BiotechTube

enzalutamide

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Severe Hepatic Impairment

Conditions

Severe Hepatic Impairment, Normal Hepatic Function

Trial Timeline

Aug 1, 2013 → Mar 1, 2014

NCT ID
NCT02138162

About enzalutamide

enzalutamide is a phase 1 stage product being developed by Astellas Pharma for Severe Hepatic Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT02138162. Target conditions include Severe Hepatic Impairment, Normal Hepatic Function.

What happened to similar drugs?

20 of 20 similar drugs in Severe Hepatic Impairment were approved

Approved (20) Terminated (6) Active (0)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅tacrolimusAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅CefiderocolShionogiApproved
✅Donepezil HClEisaiApproved
✅Donepezil Hydrochloride (Aricept)EisaiApproved
✅KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT05404139Phase 2Recruiting
NCT02749903Phase 2Active
NCT02799745Phase 2Completed
NCT02750358Phase 2Active
NCT02605863Phase 2Terminated
NCT02384382Phase 2Completed
NCT02441517ApprovedTerminated
NCT02507570Phase 2Completed
NCT02495974Pre-clinicalCompleted
NCT02203695Phase 2Completed
NCT02288936Phase 2Completed
NCT02669771Pre-clinicalCompleted
NCT02124668Phase 2Completed
NCT03297385Phase 2Completed
NCT02116582ApprovedCompleted
NCT02099864Phase 2Completed
NCT01977651ApprovedCompleted
NCT02138162Phase 1Completed
NCT01889238Phase 2Completed
NCT01663415Phase 2Withdrawn

Competing Products

20 competing products in Severe Hepatic Impairment

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
Drotrecogin alfa (activated)Eli LillyPhase 2
35
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
44
CT-P17 + EU-approved HumiraCelltrionPhase 3
40
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
44
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
CS-3150Daiichi SankyoPhase 3
40
tacrolimusAstellas PharmaApproved
43
Isavuconazonium Injection [Cresemba] + PlaceboAstellas PharmaPhase 3
32
AlefaceptAstellas PharmaApproved
43
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
35
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
44
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
42
CefiderocolShionogiApproved
50
eritoran tetrasodium + PlaceboEisaiPhase 3
40
Donepezil HClEisaiApproved
43
Donepezil Hydrochloride (Aricept)EisaiApproved
35
KHK4827 + PlaceboKyowa KirinPhase 3
40
KHK4827 + PlaceboKyowa KirinPhase 3
40